Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn

Interventions

DRUG: EDG-5506 Tablet
DRUG: Radiolabeled EDG-5506 Suspension
DRUG: Radiolabeled EDG-5506 Intravenous

Sponsor

Edgewise Therapeutics, Inc.